JP2015504306A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504306A5 JP2015504306A5 JP2014541658A JP2014541658A JP2015504306A5 JP 2015504306 A5 JP2015504306 A5 JP 2015504306A5 JP 2014541658 A JP2014541658 A JP 2014541658A JP 2014541658 A JP2014541658 A JP 2014541658A JP 2015504306 A5 JP2015504306 A5 JP 2015504306A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- represented
- region
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 24
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 24
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 16
- 150000007523 nucleic acids Chemical group 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 208000037914 B-cell disorder Diseases 0.000 claims description 4
- 241000282553 Macaca Species 0.000 claims description 4
- 208000021161 Plasma cell disease Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000007452 Plasmacytoma Diseases 0.000 claims description 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims description 2
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims description 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 2
- 206010002022 amyloidosis Diseases 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims description 2
- 208000025750 heavy chain disease Diseases 0.000 claims description 2
- 102000046935 human TNFRSF17 Human genes 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000031223 plasma cell leukemia Diseases 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims 2
- 230000000875 corresponding effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161560144P | 2011-11-15 | 2011-11-15 | |
| US201161560149P | 2011-11-15 | 2011-11-15 | |
| US201161560183P | 2011-11-15 | 2011-11-15 | |
| US201161560178P | 2011-11-15 | 2011-11-15 | |
| US201161560162P | 2011-11-15 | 2011-11-15 | |
| US61/560,183 | 2011-11-15 | ||
| US61/560,162 | 2011-11-15 | ||
| US61/560,144 | 2011-11-15 | ||
| US61/560,149 | 2011-11-15 | ||
| US61/560,178 | 2011-11-15 | ||
| US201261651474P | 2012-05-24 | 2012-05-24 | |
| US201261651486P | 2012-05-24 | 2012-05-24 | |
| US61/651,486 | 2012-05-24 | ||
| US61/651,474 | 2012-05-24 | ||
| PCT/EP2012/072699 WO2013072406A1 (en) | 2011-11-15 | 2012-11-15 | Binding molecules for bcma and cd3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017212359A Division JP6738314B2 (ja) | 2011-11-15 | 2017-11-02 | Ｂｃｍａおよびｃｄ３に対する結合分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504306A JP2015504306A (ja) | 2015-02-12 |
| JP2015504306A5 true JP2015504306A5 (enExample) | 2015-11-26 |
| JP6378087B2 JP6378087B2 (ja) | 2018-08-22 |
Family
ID=47388493
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541658A Active JP6378087B2 (ja) | 2011-11-15 | 2012-11-15 | Ｂｃｍａおよびｃｄ３に対する結合分子 |
| JP2014541660A Active JP6231007B2 (ja) | 2011-11-15 | 2012-11-15 | Ｂｃｍａおよびｃｄ３に対する結合分子 |
| JP2017110658A Pending JP2017195889A (ja) | 2011-11-15 | 2017-06-05 | Ｂｃｍａおよびｃｄ３に対する結合分子 |
| JP2017212359A Active JP6738314B2 (ja) | 2011-11-15 | 2017-11-02 | Ｂｃｍａおよびｃｄ３に対する結合分子 |
| JP2020122548A Active JP7250736B2 (ja) | 2011-11-15 | 2020-07-17 | Ｂｃｍａおよびｃｄ３に対する結合分子 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541660A Active JP6231007B2 (ja) | 2011-11-15 | 2012-11-15 | Ｂｃｍａおよびｃｄ３に対する結合分子 |
| JP2017110658A Pending JP2017195889A (ja) | 2011-11-15 | 2017-06-05 | Ｂｃｍａおよびｃｄ３に対する結合分子 |
| JP2017212359A Active JP6738314B2 (ja) | 2011-11-15 | 2017-11-02 | Ｂｃｍａおよびｃｄ３に対する結合分子 |
| JP2020122548A Active JP7250736B2 (ja) | 2011-11-15 | 2020-07-17 | Ｂｃｍａおよびｃｄ３に対する結合分子 |
Country Status (40)
Families Citing this family (190)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010037835A2 (en) * | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| PL2817338T3 (pl) | 2012-02-24 | 2017-12-29 | Abbvie Stemcentrx Llc | Modulatory DLL3 i sposoby zastosowania |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| CN104968682A (zh) * | 2013-02-05 | 2015-10-07 | 英格玛布股份公司 | 针对CD3ε和BCMA的双特异性抗体 |
| EP2762496A1 (en) * | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| PL2958944T3 (pl) | 2013-02-22 | 2019-09-30 | Abbvie Stemcentrx Llc | Koniugaty przeciwciało anty-DLL3-PBD i ich zastosowania |
| AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| KR20160044042A (ko) | 2013-08-28 | 2016-04-22 | 스템센트알엑스 인코포레이티드 | 부위-특이적 항체 접합 방법 및 조성물 |
| CA2926428C (en) | 2013-10-09 | 2023-08-29 | Research Development Foundation | Monoclonal olfml-3 antibodies and uses thereof |
| GB201317928D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| AU2015213437B2 (en) | 2014-02-07 | 2018-04-05 | Mcmaster University | Trifunctional T cell-antigen coupler and methods and uses thereof |
| CA2939941A1 (en) | 2014-02-21 | 2015-08-27 | Abbvie Stemcentrx Llc | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| EP3110838B1 (en) * | 2014-02-27 | 2019-06-26 | UCL Business Plc. | April variants |
| AU2015248956B2 (en) * | 2014-04-14 | 2020-06-25 | Cellectis | BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy |
| RU2016151645A (ru) | 2014-07-01 | 2018-08-03 | Пфайзер Инк. | Биспецифические гетеродимерные диантитела и их применение |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| JP2017536341A (ja) * | 2014-10-09 | 2017-12-07 | エンクマフ アーゲー | 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体 |
| CA2960929A1 (en) | 2014-11-20 | 2016-05-26 | F. Hoffmann-La Roche Ag | T cell activating bispecific antigen binding molecules against folr1 and cd3 |
| EP3023437A1 (en) * | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| HRP20201156T1 (hr) | 2014-11-20 | 2020-11-13 | F. Hoffmann - La Roche Ag | Zajednički laki lanci i postupci primjene |
| EP3029068A1 (en) * | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
| WO2016090320A1 (en) * | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| BR112017011914A2 (pt) * | 2014-12-05 | 2018-02-27 | Memorial Sloan-Kettering Cancer Center | ?antígeno de maturação de célula b de direcionamento de anticorpos e métodos de uso? |
| EP4481401A3 (en) * | 2015-02-24 | 2025-04-23 | The University of British Columbia | Continuous flow microfluidic system and method |
| TWI703159B (zh) | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| ES3039918T3 (en) | 2015-04-13 | 2025-10-27 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
| LT3294319T (lt) * | 2015-05-13 | 2024-08-12 | Ablynx Nv | T ląsteles sutelkiantys polipeptidai pagal cd3 reaktyvumą |
| KR20180029201A (ko) | 2015-05-18 | 2018-03-20 | 티씨알2 테라퓨틱스 인크. | 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법 |
| KR101997241B1 (ko) | 2015-05-21 | 2019-07-09 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| CN108350073B (zh) | 2015-08-03 | 2022-03-18 | 英格玛布有限责任公司 | 针对bcma的单克隆抗体 |
| JP7026613B2 (ja) | 2015-08-07 | 2022-02-28 | イマジナブ・インコーポレーテッド | 標的分子に対する抗原結合コンストラクト |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| IL320478A (en) * | 2015-08-17 | 2025-06-01 | Janssen Biotech Inc | Anti-BCMA antibodies, bispecific antigen-binding molecules that bind BCMA and CD3, and uses thereof |
| RU2022108079A (ru) | 2015-09-24 | 2022-04-08 | Дайити Санкио Компани, Лимитед | Антитело против garp |
| ES2970864T3 (es) | 2015-11-25 | 2024-05-31 | Visterra Inc | Moléculas de anticuerpos contra APRIL y usos de las mismas |
| JOP20170017B1 (ar) * | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
| KR102688969B1 (ko) * | 2016-02-03 | 2024-07-30 | 암젠 리서치 (뮌헨) 게엠베하 | Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물 |
| WO2017134158A1 (en) | 2016-02-03 | 2017-08-10 | Amgen Research (Munich) Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs |
| RS64266B1 (sr) | 2016-03-22 | 2023-07-31 | Hoffmann La Roche | Bispecifični molekul koji aktivira t ćeliju koji se aktivira proteazom |
| CN117903307A (zh) * | 2016-04-01 | 2024-04-19 | 凯德药业股份有限公司 | Bcma结合分子及其使用方法 |
| JP7010491B2 (ja) | 2016-04-11 | 2022-01-26 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | ヒト化抗ｒａｇｅ抗体 |
| CN109641046B (zh) | 2016-05-20 | 2023-11-07 | 哈普恩治疗公司 | 单链可变片段cd3结合蛋白质 |
| JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス，インク． | 単一ドメイン血清アルブミン結合タンパク質 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| KR20230129583A (ko) | 2016-06-21 | 2023-09-08 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| EP4050034B1 (en) * | 2016-09-14 | 2024-05-08 | TeneoOne, Inc. | Cd3 binding antibodies |
| IL292551B2 (en) | 2016-10-07 | 2023-10-01 | Tcr2 Therapeutics Inc | Preparations and methods for reprogramming T-cell receptors using fusion proteins |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| EP3535295A1 (en) * | 2016-11-02 | 2019-09-11 | EngMab Sàrl | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| EP3538556A1 (en) * | 2016-11-11 | 2019-09-18 | Autolus Limited | Chimeric antigen receptor |
| WO2018098365A2 (en) * | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| BR112019010602A2 (pt) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteínas trispecíficas para psma e métodos de uso |
| US10849973B2 (en) | 2016-11-23 | 2020-12-01 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
| WO2018102795A2 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| KR102633423B1 (ko) | 2016-12-21 | 2024-02-06 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| AU2018219348A1 (en) * | 2017-02-10 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Proteins binding BCMA, NKG2D and CD16 |
| AU2018222749B2 (en) | 2017-02-17 | 2024-04-18 | Fred Hutchinson Cancer Center | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders |
| CN110382539B (zh) | 2017-02-28 | 2023-08-08 | 阿菲姆德股份有限公司 | 用于cd16a定向的nk细胞结合的串联双抗体 |
| WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2018209304A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| CA3067584A1 (en) * | 2017-06-20 | 2018-12-27 | Teneobio, Inc. | Anti-bcma heavy chain-only antibodies |
| WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
| WO2019028316A1 (en) | 2017-08-03 | 2019-02-07 | Amgen Inc. | INTERLEUKIN-21 MUTÉINS AND METHODS OF TREATMENT |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CN118903386A (zh) | 2017-08-24 | 2024-11-08 | 诺和诺德股份有限公司 | Glp-1组合物及其用途 |
| AR112797A1 (es) | 2017-09-08 | 2019-12-11 | Amgen Inc | Inhibidores de kras g12c y métodos para utilizarlos |
| CN111107874A (zh) | 2017-09-14 | 2020-05-05 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于癌症的组合治疗 |
| CA3075714A1 (en) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| CA3075717A1 (en) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| CN111479925B (zh) | 2017-10-12 | 2024-03-08 | 麦克马斯特大学 | 具有y182t突变的t细胞-抗原偶联物及其方法和用途 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| WO2019075359A1 (en) * | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS AND METHODS OF USE |
| KR20200086278A (ko) | 2017-10-18 | 2020-07-16 | 노파르티스 아게 | 선택적 단백질 분해를 위한 조성물 및 방법 |
| EP3703750B1 (en) | 2017-11-01 | 2024-12-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides |
| CN111511370A (zh) | 2017-11-01 | 2020-08-07 | 朱诺治疗学股份有限公司 | 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体 |
| MA50564A (fr) | 2017-11-06 | 2020-09-16 | Hutchinson Fred Cancer Res | Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase |
| JP2021502979A (ja) | 2017-11-15 | 2021-02-04 | ノバルティス アーゲー | Ｂｃｍａターゲティングキメラ抗原受容体、ｃｄ１９ターゲティングキメラ抗原受容体及び併用療法 |
| KR20200096253A (ko) | 2017-11-30 | 2020-08-11 | 노파르티스 아게 | Bcma-표적화 키메라 항원 수용체, 및 이의 용도 |
| EP3728319A1 (en) | 2017-12-22 | 2020-10-28 | TeneoBio, Inc. | Heavy chain antibodies binding to cd22 |
| KR20200104364A (ko) * | 2017-12-27 | 2020-09-03 | 테네오바이오, 인코포레이티드 | Cd3-델타/엡실론 이형이량체 특이적 항체 |
| CN117050184A (zh) | 2017-12-28 | 2023-11-14 | 南京传奇生物科技有限公司 | 针对tigit的单域抗体和其变体 |
| CN112218651A (zh) | 2018-01-08 | 2021-01-12 | 诺华公司 | 用于与嵌合抗原受体疗法组合的免疫增强rna |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| ES2941740T3 (es) | 2018-01-12 | 2023-05-25 | Amgen Inc | Anticuerpos anti-PD-1 y métodos de tratamiento |
| KR20250114571A (ko) | 2018-01-15 | 2025-07-29 | 난징 레전드 바이오테크 씨오., 엘티디. | Pd-1에 대한 단일-도메인 항체 및 이의 변이체 |
| US12286478B2 (en) | 2018-01-23 | 2025-04-29 | Nextcure, Inc. | B7-H4 antibodies and methods of use thereof |
| US20210038659A1 (en) | 2018-01-31 | 2021-02-11 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| CN112119099A (zh) | 2018-03-02 | 2020-12-22 | Cdr-生物科技股份有限公司 | 三特异性抗原结合蛋白 |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CN110372796B (zh) * | 2018-04-12 | 2023-05-02 | 上海赛比曼生物科技有限公司 | 靶向bcma的嵌合抗原受体及其制法和应用 |
| KR20200143436A (ko) | 2018-04-13 | 2020-12-23 | 아피메트 게엠베하 | Nk 세포 결합 항체 융합 구조체 |
| US12415860B2 (en) | 2018-05-14 | 2025-09-16 | Harpoon Therapeutics, Inc. | Binding moiety for conditional activation of immunoglobulin molecules |
| MX2020012286A (es) | 2018-05-16 | 2021-04-28 | Janssen Biotech Inc | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t. |
| UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| CN112533633A (zh) | 2018-06-08 | 2021-03-19 | 伊麦吉纳博公司 | Cd4的抗原结合构建体 |
| DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
| US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| SMT202400102T1 (it) | 2018-07-19 | 2024-05-14 | Regeneron Pharma | Recettori chimerici dell’antigene con specificità per bcma e loro usi |
| JP7439046B2 (ja) | 2018-07-20 | 2024-02-27 | テネオツー・インコーポレイテッド | Ｃｄ１９に結合する重鎖抗体 |
| TW202019477A (zh) | 2018-07-31 | 2020-06-01 | 德商安美基研究（慕尼黑）公司 | BCMAxCD3抗體構建體之給藥方案 |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| BR112020024296A2 (pt) | 2018-08-27 | 2021-03-09 | Regeneron Pharmaceuticals, Inc. | Métodos para produção de um intermediário de purificação de proteína concentrado, para monitoramento e controle dos atributos de qualidade críticos em um intermediário de purificação de proteína e para monitorar e controlar os níveis de excipientes no fluido de cultura de células colhido e/ou intermediário de purificação de proteína, e, intermediário de purificação de proteína |
| EP4431597A3 (en) * | 2018-08-27 | 2025-03-05 | Affimed GmbH | Cryopreserved nk cells preloaded with an antibody construct |
| CN112639083A (zh) | 2018-08-31 | 2021-04-09 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
| US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
| FI3844189T3 (fi) | 2018-08-31 | 2025-03-05 | Regeneron Pharma | Annostusstrategia, joka lieventää bispesifisten CD3/CD20-vasta-aineiden sytokiinien vapautumisoireyhtymää |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| BR112021005769A2 (pt) | 2018-09-25 | 2021-07-06 | Harpoon Therapeutics Inc | proteínas de ligação a dll3 e métodos de uso |
| KR20210068408A (ko) * | 2018-09-28 | 2021-06-09 | 암젠 인크 | 가용성 bcma에 대한 항체 |
| CN109503716B (zh) * | 2018-10-08 | 2021-04-27 | 浙江生研生物科技有限公司 | 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用 |
| CA3118191A1 (en) | 2018-10-31 | 2020-05-07 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| CN111138542B (zh) | 2018-11-01 | 2022-09-23 | 山东新时代药业有限公司 | 双特异性抗体及其用途 |
| EP3873943A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| SG11202108955QA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Antibody molecules that bind to nkp30 and uses thereof |
| CA3126087A1 (en) | 2019-02-25 | 2020-09-03 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| CN113597328B (zh) | 2019-03-21 | 2025-10-31 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| US20230074800A1 (en) | 2019-03-21 | 2023-03-09 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
| KR20210149076A (ko) | 2019-04-05 | 2021-12-08 | 테네오바이오, 인코포레이티드 | Psma에 결합하는 중쇄 항체 |
| US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| BR112021024956A2 (pt) | 2019-06-14 | 2022-01-25 | Teneobio Inc | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 |
| WO2020261093A1 (en) * | 2019-06-24 | 2020-12-30 | Novartis Ag | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen |
| CN112204135A (zh) * | 2019-07-06 | 2021-01-08 | 苏州克睿基因生物科技有限公司 | 一种表达cd3抗体受体复合物的免疫细胞及其用途 |
| WO2021004400A1 (zh) * | 2019-07-06 | 2021-01-14 | 苏州克睿基因生物科技有限公司 | 一种表达cd3抗体受体复合物的免疫细胞及其用途 |
| US20220289859A1 (en) | 2019-08-06 | 2022-09-15 | Glaxosmithkline Intellectual Property Development Limited | Biopharmacuetical Compositions and Related Methods |
| JP2022548943A (ja) * | 2019-09-25 | 2022-11-22 | フェイト セラピューティクス，インコーポレイテッド | 複数標的化エフェクター細胞およびその使用 |
| JP2022551662A (ja) * | 2019-10-10 | 2022-12-12 | 蘇州親為薬業有限公司 | Ｂｃｍａを標的とする、ヒトサルの交差反応性を有するヒト化モノクローナル抗体 |
| EP3819007B1 (en) | 2019-11-11 | 2024-07-10 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
| TW202134264A (zh) | 2019-11-26 | 2021-09-16 | 瑞士商諾華公司 | 嵌合抗原受體及其用途 |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| KR20220143036A (ko) | 2020-02-18 | 2022-10-24 | 노보 노르디스크 에이/에스 | 약학적 제형 |
| BR112022016550A2 (pt) | 2020-02-21 | 2022-11-16 | Harpoon Therapeutics Inc | Proteínas de ligação a flt3 e métodos de uso |
| WO2021173985A2 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| MX2022010685A (es) | 2020-02-27 | 2022-09-23 | Novartis Ag | Metodos de produccion de celulas que expresan receptores de antigeno quimericos. |
| AU2021240028A1 (en) | 2020-03-19 | 2022-09-15 | Amgen Inc. | Antibodies against mucin 17 and uses thereof |
| CA3214992A1 (en) | 2020-04-29 | 2021-11-04 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| IL297644A (en) | 2020-04-29 | 2022-12-01 | Teneobio Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| TWI894270B (zh) | 2020-05-11 | 2025-08-21 | 美商健生生物科技公司 | 用於治療多發性骨髓瘤之方法 |
| CA3183905A1 (en) | 2020-05-19 | 2021-11-25 | Janssen Biotech, Inc | Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor |
| EP4165169A1 (en) | 2020-06-11 | 2023-04-19 | Novartis AG | Zbtb32 inhibitors and uses thereof |
| PE20230464A1 (es) | 2020-06-30 | 2023-03-14 | Teneobio Inc | Union de anticuerpos multiespecificos a bcma |
| CA3188978A1 (en) | 2020-08-21 | 2022-02-24 | Sandeep Tharian Koshy | Compositions and methods for in vivo generation of car expressing cells |
| AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
| WO2022103781A1 (en) | 2020-11-10 | 2022-05-19 | Amgen Inc. | Methods for administering a bcma x cd3 binding molecule |
| CN114573703A (zh) * | 2020-12-02 | 2022-06-03 | 康诺亚生物医药科技（成都）有限公司 | 一种t细胞衔接器治疗剂的开发和应用 |
| WO2022135468A1 (zh) * | 2020-12-23 | 2022-06-30 | 信达生物制药(苏州)有限公司 | 抗bcma×cd3双特异性抗体及其用途 |
| CN114763383B (zh) * | 2021-01-13 | 2024-12-17 | 博生吉医药科技(苏州)有限公司 | 靶向人bcma的单克隆抗体及其应用 |
| US12274747B2 (en) | 2021-01-28 | 2025-04-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
| AU2022267891A1 (en) | 2021-04-27 | 2023-11-09 | Novartis Ag | Viral vector production system |
| WO2022248870A1 (en) | 2021-05-28 | 2022-12-01 | Glaxosmithkline Intellectual Property Development Limited | Combination therapies for treating cancer |
| CA3173810A1 (en) | 2021-06-01 | 2022-12-01 | Andreas Bader | Claudin 18.2 t cell-antigen couplers and uses thereof |
| CN119569887A (zh) * | 2021-06-24 | 2025-03-07 | 益科思特(北京)医药科技发展有限公司 | 结合bcma和cd3的双特异性抗体及其制备方法与应用 |
| US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
| KR20240040786A (ko) | 2021-08-03 | 2024-03-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 생물제약 조성물 및 안정한 동위원소 표지 펩티드 맵핑 방법 |
| AR126838A1 (es) | 2021-08-20 | 2023-11-22 | Novartis Ag | Métodos para preparar células que expresan receptores de antígeno quiméricos |
| JP2024537863A (ja) | 2021-10-05 | 2024-10-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | がんを処置するための組合せ療法 |
| AU2022380722A1 (en) | 2021-11-03 | 2024-06-20 | Janssen Biotech, Inc. | Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies |
| EP4469484A1 (en) | 2022-01-25 | 2024-12-04 | GlaxoSmithKline Intellectual Property Development Ltd | Combination therapy for cancer |
| CA3247475A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharma | COMPOSITIONS AND METHODS FOR THE DESTRUCTION OF UNIVERSAL TUMOR CELLS |
| AU2023369684A1 (en) | 2022-10-26 | 2025-04-17 | Novartis Ag | Lentiviral formulations |
| CN120303298A (zh) | 2022-12-05 | 2025-07-11 | 葛兰素史密斯克莱知识产权发展有限公司 | 使用b细胞成熟抗原拮抗剂的治疗方法 |
| KR20250151441A (ko) | 2023-02-17 | 2025-10-21 | 리제너론 파마슈티칼스 인코포레이티드 | Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포 |
| US12173081B2 (en) | 2023-03-21 | 2024-12-24 | Biograph 55, Inc. | CD19/CD38 multispecific antibodies |
| CN120641113A (zh) | 2023-03-31 | 2025-09-12 | 西比曼生物科技集团 | 靶向cd20和bcma的双特异性嵌合抗原受体 |
| WO2024215708A2 (en) * | 2023-04-11 | 2024-10-17 | AbelZeta Inc. | Bispecific chimeric antigen receptors targeting bcma and cd19 |
| TW202502811A (zh) | 2023-06-01 | 2025-01-16 | 瑞士商赫孚孟拉羅股份公司 | 與ｂｃｍａ特異性結合之免疫刺激性抗原結合分子 |
| WO2024246083A1 (en) | 2023-06-01 | 2024-12-05 | F. Hoffmann-La Roche Ag | Bispecific antibodies targeting bcma and cd28 |
| WO2025160324A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025160340A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025174963A1 (en) | 2024-02-16 | 2025-08-21 | Kite Pharma, Inc. | Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (215)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2003A (en) | 1841-03-12 | Improvement in horizontal windivhlls | ||
| US4816A (en) | 1846-10-17 | Bell machinery for hotels | ||
| US556A (en) | 1838-01-09 | Machine foe | ||
| US5013A (en) | 1847-03-13 | Improvement in apparatus for the manufacture of malleable iron | ||
| US567A (en) | 1838-01-09 | Machine for r-uibbii | ||
| US70185A (en) | 1867-10-29 | fan oh be | ||
| US1985A (en) | 1841-02-18 | Charles m | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4281061A (en) | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4475916A (en) | 1982-03-18 | 1984-10-09 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP0839536A1 (en) | 1989-10-27 | 1998-05-06 | Arch Development Corporation | Methods and compositions for promoting immunopotentiation |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2142801T3 (es) | 1991-03-11 | 2000-05-01 | Univ Georgia Res Found | Clonacion y expresion de luciferasa de renilla. |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
| DE69435112D1 (de) | 1993-09-10 | 2008-08-21 | Univ Columbia | Verwendung von grünem fluoreszenzprotein |
| WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6037453A (en) | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| EP2258726A1 (en) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| CA2230759C (en) | 1995-08-29 | 2012-02-21 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for producing the same |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
| US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
| US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| IL129767A0 (en) | 1996-12-12 | 2000-02-29 | Prolume Ltd | Apparatus and method for detecting and identifying infectious agents |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| JP2001518328A (ja) | 1997-10-01 | 2001-10-16 | ボストン サイエンティフィック リミテッド | 拡張システムおよび関連方法 |
| EP1071752B1 (en) | 1998-04-21 | 2003-07-09 | Micromet AG | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| WO1999066951A2 (en) | 1998-06-22 | 1999-12-29 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| AU5728999A (en) | 1998-07-28 | 2000-02-21 | Micromet Ag | Heterominibodies |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| WO2000040716A2 (en) | 1999-01-07 | 2000-07-13 | Zymogenetics, Inc. | Soluble receptor br43x2 and methods of using them for therapy |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| WO2001012812A2 (en) | 1999-08-17 | 2001-02-22 | Biogen, Inc. | Baff receptor (bcma), an immunoregulatory agent |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| ATE361318T1 (de) | 2000-05-12 | 2007-05-15 | Amgen Inc | Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen |
| SV2007000775A (es) | 2001-01-05 | 2007-03-15 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
| EP1362061A2 (en) | 2001-02-20 | 2003-11-19 | ZymoGenetics, Inc. | Antibodies that bind both bcma and taci |
| IL159225A0 (en) | 2001-06-13 | 2004-06-01 | Genmab As | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| AU2002348263B2 (en) | 2001-11-30 | 2008-10-16 | Amgen Fremont Inc. | Transgenic animals bearing human IgLamda light chain genes |
| AU2003224916B2 (en) | 2002-04-10 | 2009-01-08 | Genentech, Inc. | Anti-HER2 antibody variants |
| AU2003223683A1 (en) | 2002-04-22 | 2003-11-03 | Georgetown University | Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration |
| WO2005056606A2 (en) | 2003-12-03 | 2005-06-23 | Xencor, Inc | Optimized antibodies that target the epidermal growth factor receptor |
| AU2004242845B2 (en) | 2003-05-31 | 2011-06-02 | Amgen Research (Munich) Gmbh | Human-anti-human CD3 binding molecules |
| US7919089B2 (en) | 2003-05-31 | 2011-04-05 | Micromet Ag | Pharmaceutical composition comprising a bispecific antibody for EpCAM |
| WO2004106381A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| RU2401843C2 (ru) | 2003-10-16 | 2010-10-20 | Микромет Аг | Полиспецифические деиммунизирующие cd3-связующие |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| JP4541014B2 (ja) | 2004-01-13 | 2010-09-08 | キヤノンアネルバ株式会社 | プラズマ支援スパッタ成膜装置 |
| WO2005075511A1 (en) | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants of the extracellular domain of bcma and uses thereof |
| EP1716178B1 (en) * | 2004-02-16 | 2010-08-11 | Micromet AG | Less immunogenic binding molecules |
| MXPA06011526A (es) | 2004-04-06 | 2007-03-21 | Novimmune Sa | Metodos de tratamiento de enfermedades autoinmunes e inflamatorias. |
| SG155883A1 (en) | 2004-06-03 | 2009-10-29 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| CA2577133A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | SELF-BUFFING PROTEIN FORMULATIONS |
| CA2614640A1 (en) | 2005-07-11 | 2007-01-18 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| US20100209437A1 (en) | 2005-09-12 | 2010-08-19 | Greg Elson | Anti-CD3 Antibody Fromulations |
| CN101370830A (zh) * | 2005-09-26 | 2009-02-18 | 米德列斯公司 | 抗cd70的人单克隆抗体 |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| EP1945674A2 (en) | 2005-11-03 | 2008-07-23 | Genentech, Inc. | Therapeutic anti-her2 antibody fusion polypeptides |
| JP6088723B2 (ja) | 2005-11-23 | 2017-03-01 | ジェネンテック， インコーポレイテッド | Ｂ細胞アッセイに関する組成物及び方法。 |
| US20070264687A1 (en) | 2005-12-15 | 2007-11-15 | Min-Yuan Chou | Recombinant triplex scaffold-based polypeptides |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| MX363905B (es) | 2006-06-12 | 2019-04-08 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| EP4059964A1 (en) | 2007-04-03 | 2022-09-21 | Amgen Research (Munich) GmbH | Cross-species-specific binding domain |
| EP2155783B2 (en) | 2007-04-03 | 2022-10-19 | Amgen Research (Munich) GmbH | Cross-species-specific cd3-epsilon binding domain |
| US20230357444A1 (en) | 2007-04-03 | 2023-11-09 | Amgen Research (Munich) Gmbh | Cross-species-specific binding domain |
| MX2009010611A (es) | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
| WO2008131242A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| US7998018B2 (en) | 2007-04-30 | 2011-08-16 | GM Global Technology Operations LLC | Multi-speed transmission |
| KR20100021601A (ko) | 2007-05-14 | 2010-02-25 | 바이오겐 아이덱 엠에이 인코포레이티드 | 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법 |
| WO2009132058A2 (en) * | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| WO2010037835A2 (en) * | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| HUE030090T2 (en) | 2008-10-01 | 2017-04-28 | Amgen Res Munich Gmbh | Cross-species-specific psmaxcd3 bispecific single chain antibody |
| US10981998B2 (en) | 2008-10-01 | 2021-04-20 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| CA2738566C (en) | 2008-10-01 | 2024-04-30 | Micromet Ag | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| JP2012509658A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | Ｉｌ−１３に結合するリガンド |
| NZ612647A (en) | 2009-03-10 | 2015-03-27 | Biogen Idec Inc | Anti-bcma antibodies |
| AU2010245011B2 (en) | 2009-04-27 | 2015-09-03 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| CN103154034B (zh) | 2010-04-13 | 2016-06-08 | 塞尔德克斯医疗公司 | 结合人cd27的抗体及其用途 |
| CA2800173C (en) | 2010-05-21 | 2019-05-14 | Ulrik Nielsen | Bi-specific fusion proteins |
| US9410994B2 (en) | 2010-11-15 | 2016-08-09 | Lg Electronics Inc. | Refrigerator and operation method thereof |
| US20130273055A1 (en) | 2010-11-16 | 2013-10-17 | Eric Borges | Agents and methods for treating diseases that correlate with bcma expression |
| TWI736437B (zh) | 2010-11-30 | 2021-08-11 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| WO2012088461A2 (en) | 2010-12-23 | 2012-06-28 | Biogen Idec Inc. | Linker peptides and polypeptides comprising same |
| SG194176A1 (en) | 2011-05-27 | 2013-12-30 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| AR087608A1 (es) | 2011-08-23 | 2014-04-03 | Roche Glycart Ag | Moleculas biespecificas de union a antigeno activadoras de celulas t |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| BR112015000798A2 (pt) | 2012-07-13 | 2017-06-27 | Zymeworks Inc | heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| EP2731280B8 (en) | 2012-11-07 | 2019-03-20 | Telefonaktiebolaget LM Ericsson (publ) | Loopback-based built-in-self-test |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| DK2943511T3 (da) | 2013-01-14 | 2019-10-21 | Xencor Inc | Nye heterodimeriske proteiner |
| JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| CN104968682A (zh) | 2013-02-05 | 2015-10-07 | 英格玛布股份公司 | 针对CD3ε和BCMA的双特异性抗体 |
| TW201444872A (zh) | 2013-03-06 | 2014-12-01 | Merrimack Pharmaceuticals Inc | 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體 |
| ES2753950T3 (es) | 2013-03-15 | 2020-04-15 | Amgen Res Munich Gmbh | Moléculas de unión monocatenarias que comprenden ABP del extremo N |
| AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| EP3733710A1 (en) | 2013-09-25 | 2020-11-04 | Amgen, Inc | Hetrodimeric v-c-fc-v-c antibody |
| EP3174901B1 (en) | 2014-07-31 | 2019-06-26 | Amgen Research (Munich) GmbH | Optimized cross-species specific bispecific single chain antibody constructs |
| HUE055115T2 (hu) | 2014-11-26 | 2021-10-28 | Xencor Inc | CD3-at és CD20-at kötõ heterodimer antitestek |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| JP6907124B2 (ja) | 2015-04-17 | 2021-07-21 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ | Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TW202346349A (zh) | 2015-07-31 | 2023-12-01 | 德商安美基研究（慕尼黑）公司 | Dll3及cd3抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| KR102688969B1 (ko) | 2016-02-03 | 2024-07-30 | 암젠 리서치 (뮌헨) 게엠베하 | Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물 |
| WO2017134158A1 (en) | 2016-02-03 | 2017-08-10 | Amgen Research (Munich) Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs |
| EP3535295A1 (en) | 2016-11-02 | 2019-09-11 | EngMab Sàrl | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| IL270239B2 (en) | 2017-05-05 | 2025-01-01 | Amgen Inc | Pharmaceutical composition containing bispecific antibody constructs for improved storage and delivery |
-
2012
- 2012-11-14 TW TW101142376A patent/TWI679212B/zh active
- 2012-11-15 AR ARP120104307 patent/AR088883A1/es active IP Right Grant
- 2012-11-15 US US13/678,247 patent/US9340621B2/en active Active
- 2012-11-15 JP JP2014541658A patent/JP6378087B2/ja active Active
- 2012-11-15 CN CN201280056358.5A patent/CN104169300A/zh active Pending
- 2012-11-15 CA CA 2850591 patent/CA2850591A1/en not_active Abandoned
- 2012-11-15 PL PL12805432T patent/PL2780375T3/pl unknown
- 2012-11-15 SI SI201231673T patent/SI2780375T1/sl unknown
- 2012-11-15 LT LT12805432T patent/LT2780375T/lt unknown
- 2012-11-15 SG SG11201401729PA patent/SG11201401729PA/en unknown
- 2012-11-15 SM SM20190627T patent/SMT201900627T1/it unknown
- 2012-11-15 PH PH1/2014/501076A patent/PH12014501076A1/en unknown
- 2012-11-15 EP EP19196304.0A patent/EP3611193A1/en active Pending
- 2012-11-15 DK DK12805432T patent/DK2780375T3/da active
- 2012-11-15 GE GEAP201213496A patent/GEP20186928B/en unknown
- 2012-11-15 BR BR112014010630-4A patent/BR112014010630B1/pt active IP Right Grant
- 2012-11-15 CN CN201280056357.0A patent/CN104114578B/zh active Active
- 2012-11-15 JP JP2014541660A patent/JP6231007B2/ja active Active
- 2012-11-15 EP EP24219338.1A patent/EP4512481A3/en active Pending
- 2012-11-15 EA EA201490932A patent/EA201490932A1/ru unknown
- 2012-11-15 MX MX2014005852A patent/MX349396B/es active IP Right Grant
- 2012-11-15 PE PE2014000669A patent/PE20141564A1/es active IP Right Grant
- 2012-11-15 EA EA201490931A patent/EA028162B1/ru not_active IP Right Cessation
- 2012-11-15 EP EP19192268.1A patent/EP3623385A1/en active Pending
- 2012-11-15 KR KR20147016300A patent/KR20140105758A/ko not_active Withdrawn
- 2012-11-15 RS RSP20191279 patent/RS59373B1/sr unknown
- 2012-11-15 WO PCT/EP2012/072699 patent/WO2013072406A1/en not_active Ceased
- 2012-11-15 CN CN201811036957.6A patent/CN109485729A/zh active Pending
- 2012-11-15 US US14/358,520 patent/US9598500B2/en active Active
- 2012-11-15 KR KR1020217007556A patent/KR102346029B1/ko active Active
- 2012-11-15 HR HRP20191697 patent/HRP20191697T1/hr unknown
- 2012-11-15 UY UY34453A patent/UY34453A/es active IP Right Grant
- 2012-11-15 HU HUE12805432A patent/HUE046682T2/hu unknown
- 2012-11-15 PT PT128054327T patent/PT2780375T/pt unknown
- 2012-11-15 KR KR1020197038468A patent/KR102229469B1/ko active Active
- 2012-11-15 MY MYPI2014001357A patent/MY189544A/en unknown
- 2012-11-15 SG SG10201704483RA patent/SG10201704483RA/en unknown
- 2012-11-15 MX MX2014005851A patent/MX2014005851A/es unknown
- 2012-11-15 US US14/358,511 patent/US10766969B2/en active Active
- 2012-11-15 ME MEP-2019-270A patent/ME03521B/me unknown
- 2012-11-15 AP AP2014007529A patent/AP2014007529A0/xx unknown
- 2012-11-15 EP EP12805432.7A patent/EP2780375B1/en not_active Revoked
- 2012-11-15 US US13/678,264 patent/US9150664B2/en active Active
- 2012-11-15 WO PCT/EP2012/072730 patent/WO2013072415A1/en not_active Ceased
- 2012-11-15 BR BR112014010940A patent/BR112014010940A2/pt not_active Application Discontinuation
- 2012-11-15 UY UY34454A patent/UY34454A/es not_active Application Discontinuation
- 2012-11-15 SG SG11201400671YA patent/SG11201400671YA/en unknown
- 2012-11-15 ES ES12803509T patent/ES2749451T3/es active Active
- 2012-11-15 UA UAA201405451A patent/UA116766C2/uk unknown
- 2012-11-15 AU AU2012327203A patent/AU2012327203A1/en not_active Abandoned
- 2012-11-15 EP EP12803509.4A patent/EP2780374B1/en not_active Revoked
- 2012-11-15 ES ES12805432T patent/ES2751996T3/es active Active
- 2012-11-15 SG SG10201606484SA patent/SG10201606484SA/en unknown
- 2012-11-15 KR KR1020147016296A patent/KR102062231B1/ko active Active
- 2012-11-15 CA CA2849196A patent/CA2849196C/en active Active
-
2014
- 2014-03-04 ZA ZA2014/01615A patent/ZA201401615B/en unknown
- 2014-03-06 TN TNP2014000097A patent/TN2014000097A1/en unknown
- 2014-03-21 TN TNP2014000121A patent/TN2014000121A1/en unknown
- 2014-03-21 MA MA36845A patent/MA35449B1/fr unknown
- 2014-03-21 MA MA36846A patent/MA35450B1/fr unknown
- 2014-05-13 IL IL232603A patent/IL232603B/en active IP Right Grant
- 2014-05-13 CL CL2014001254A patent/CL2014001254A1/es unknown
- 2014-05-14 IL IL232636A patent/IL232636A0/en unknown
- 2014-05-14 PH PH12014501091A patent/PH12014501091A1/en unknown
- 2014-06-12 EC ECIEPI20144829A patent/ECSP14004829A/es unknown
- 2014-06-13 EC ECIEPI20144893A patent/ECSP14004893A/es unknown
-
2017
- 2017-06-05 JP JP2017110658A patent/JP2017195889A/ja active Pending
- 2017-11-02 JP JP2017212359A patent/JP6738314B2/ja active Active
-
2018
- 2018-06-20 IL IL260189A patent/IL260189A/en unknown
-
2019
- 2019-11-13 CY CY20191101198T patent/CY1122543T1/el unknown
-
2020
- 2020-07-17 JP JP2020122548A patent/JP7250736B2/ja active Active
- 2020-09-03 US US17/011,849 patent/US12281175B2/en active Active
-
2021
- 2021-06-01 US US17/336,152 patent/US12281176B2/en active Active
-
2022
- 2022-02-15 US US17/672,546 patent/US20220251243A1/en not_active Abandoned
-
2023
- 2023-02-22 FR FR23C1013C patent/FR23C1013I1/fr active Active
-
2025
- 2025-01-17 US US19/030,422 patent/US20250346684A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504306A5 (enExample) | ||
| JP2014534242A5 (enExample) | ||
| JP2016511277A5 (enExample) | ||
| TWI769537B (zh) | 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途 | |
| JP7161400B2 (ja) | Ｃｄ２２に結合する抗体分子 | |
| JP2016512551A5 (enExample) | ||
| RU2495050C2 (ru) | Связующий элемент для рецептора gm-csf | |
| JP2022037133A (ja) | 改良された血清アルブミン結合剤 | |
| JP6998857B2 (ja) | Ｃｄ７９に結合する抗体分子 | |
| RU2012130840A (ru) | Соединения | |
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| JP2009537608A5 (enExample) | ||
| JP2010524435A5 (enExample) | ||
| JP2013535952A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| FI2155783T4 (fi) | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| JP2016511750A5 (enExample) | ||
| JP2017522892A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2018532766A5 (enExample) | ||
| JP2012530496A5 (enExample) | ||
| JP2012524071A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| JP2018521638A5 (enExample) | ||
| NZ596136A (en) | Anti-cd100 antibodies and methods for using the same |